Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

First-in-class, cardioprotective drug with potential to transform treatment following myocardial infarction and stenting

Oslo, Norway – 22 May 2023 – Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Read more…